Abstract
Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) is the largest, global, non-interventional, prospective study of patients with uHCC (n>3200) treated with sorafenib in real-life clinical practice conditions. Here we report the final analysis of safety and efficacy in the Italian cohort of patients.
| Titolo tradotto del contributo | [Autom. eng. transl.] [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy] |
|---|---|
| Lingua originale | Italian |
| pagine (da-a) | 217-226 |
| Numero di pagine | 10 |
| Rivista | Recenti Progressi in Medicina |
| Volume | 106 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2015 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Hepatocellular
- Female
- Humans
- Italy
- Liver Neoplasms
- Male
- Middle Aged
- Niacinamide
- Phenylurea Compounds
- Prospective Studies